{"id":503286,"date":"2025-07-25T00:00:00","date_gmt":"2025-07-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2025-biopharma-rheumatoid-arthritis-current-treatment-current-treatment-physician-insights-rheumatoid\/"},"modified":"2026-05-16T11:16:10","modified_gmt":"2026-05-16T11:16:10","slug":"cutrim0003-2025-biopharma-rheumatoid-arthritis-current-treatment-current-treatment-physician-insights-rheumatoid","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2025-biopharma-rheumatoid-arthritis-current-treatment-current-treatment-physician-insights-rheumatoid\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Rheumatoid Arthritis (EU5)"},"content":{"rendered":"<p>Many established therapies are available to treat rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>). Tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha) inhibitors are the most widely used class of agents after conventional disease-modifying anti-rheumatic drugs (<abbr title=\"conventional disease-modifying antirheumatic drug\">cDMARD<\/abbr>s) for treating the disease. However, approximately half of the patients fail to respond adequately to first-line therapy and quickly move to second-line treatment. Even in responders, the therapeutic benefit of these agents tends to diminish over time. However, in the past decade, the <abbr title=\"rheumatoid arthritis\">RA<\/abbr> market has experienced a new wave of growth, driven by the entry of biosimilars and current and emerging agents with alternative mechanisms of action, which provide new treatment options for those patients who respond inadequately to earlier lines of treatment including <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors.The availability of these new therapies is influencing physicians\u2019 prescribing practices and reshaping the overall RA treatment landscape.This report offers insight into rheumatologists\u2019 prescribing patterns, attitudes and perceptions, and current and anticipated use of various products.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW139445303 BCX0 round-bullets\">\n<li>Which drug classes are the patient-share leaders in each line of therapy? How are the various biological agents positioned in surveyed physicians\u2019 <abbr title=\"rheumatoid arthritis\">RA<\/abbr> treatment algorithm?<\/li>\n<li>What are the most influential drivers and constraints influencing physicians\u2019 treatment decisions for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>How long do patients stay on a therapy? What factors drive therapy discontinuation and switching?<\/li>\n<li>How and why have rheumatologists\u2019 prescribing practices\u00a0changed in the past year? What changes are they anticipating in the coming year?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>France, Germany, Italy, Spain, and the United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> 250 rheumatologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom.<\/p>\n<p><strong>Key drugs: <\/strong>Enbrel, Humira, Remicade, Cimzia, Simponi, Orencia, Actemra, MabThera, Olumiant, Xeljanz, Rinvoq, Jyseleca<\/p>\n<p><strong>Product description <\/strong><\/p>\n<p>Through survey data from <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW139445303 BCX0 round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-503286","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-product-current-treatment","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/503286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/503286\/revisions"}],"predecessor-version":[{"id":503597,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/503286\/revisions\/503597"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=503286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}